To evaluate the homogeneity of the 'low-risk' bladder cancer group in an attempt to optimise follow-up protocols.
Introduction
Patients diagnosed with non-muscle-invasive urothelial carcinomas are stratified into low-, intermediate-, and highrisk groups according to the European Association of Urology (EAU), National Comprehensive Cancer Network, AUA/ Society of Urologic Oncology, National Institute for Health and Care Excellence (NICE), and Canadian guidelines [1] [2] [3] [4] [5] . The 'low-risk' group includes patients with primary, solitary, Ta, low-grade tumours of <3 cm not accompanied by carcinoma in situ. The 1-year probability of tumour recurrence of these patients is 15% and the 5-year probability is 31% [6] . The risk of progression in these patients is very low (0.8% in 5 years). An immediate single-dose postoperative instillation of chemotherapy is indicated in these cases. The recommendations for surveillance in most guidelines include cystoscopy at 3 and 12 months after surgery, and then annually for a total of 5 years [1] [2] [3] , except the NICE guidelines that suggest cystoscopy at 3 and 12 months after diagnosis and then discharge to primary care [4] , and the Canadian guidelines that suggest cystoscopic examination at 3 and 9 months after surgery and annually thereafter [5] .
Tumour size is a known prognostic factor in low-grade bladder tumours [6] [7] [8] , but the 'low-risk' category embraces a rather wide range of dimensions from 0 to 3 cm. In the present study, we investigated the homogeneity of the 'lowrisk' group and whether it can be subdivided according to tumour diameter into risk groups with different clinical features.
Patients and Methods

Patient Population
A prospectively maintained database held data on 211 patients with low-risk bladder cancer, with a mean (SD, range) age of 66.7 (12.8, 25-94) years. The series included 43 women and 168 men who underwent transurethral resection of a primary, solitary, low-grade, Ta bladder tumour between June 1998 and December 2008. All patients had negative urinary cytology and negative upper tract evaluation (mostly with IVU in the early years and CT urography in later years). In 147 patients (70%), the tumour was symptomatic and in 64 (30%) it was diagnosed incidentally by ultrasonography (US) performed for a different purpose. The pathological diagnoses were made by a dedicated uropathologist that reviewed all cases. Pathological staging was performed according to the 1997 TNM system and grading according to the 1998 International Society of Urological Pathology (ISUP) classifications. The minimum follow-up for patients without recurrence was 5 years. The study was approved by the Institutional Review Board Committee (IRB number 0037-17HMO).
Patient Management
Patients had transurethral resection of the tumour and an immediate single instillation of chemotherapeutic agent doxorubicin in most cases, unless there was excessive bleeding or suspicion of bladder perforation. In these cases, the patient was connected to an irrigation system for 24 h (2 L every 4 h). The follow-up protocol was according to the EAU protocol for 5 years and afterwards with annual US of the urinary system indefinitely.
Statistical Analysis
Risk factors for recurrence and progression that were analysed included: age, gender, presentation mode (symptomatic or asymptomatic), largest tumour diameter, and the presence of an endophytic growth pattern. Continuous variables were compared using the t-test and categorical variables using Fisher's exact test. Significant variables were further evaluated with multivariate logistic regression. Recurrence-free survival (RFS) and progression-free survival were analysed using the Kaplan-Meier method. All statistical tests were two-tailed and a P < 0.05 was considered statistically significant. JMP software (SAS Institute Inc., Cary, NC, USA) was used for data processing.
Results
The study cohort included 211 patients that were followed for a median (range) period of 10 (5-14.4) years. Patients' characteristics and recurrence patterns are presented in Table 1 . Recurrence was diagnosed in 65 patients (30.7%) after a median period of 3.15 years. In univariate analysis, the recurrence rate was significantly higher in female patients (P = 0.039) and in patients with tumours >1 cm (P = 0.012). Only tumour size remained a significant prognostic factor in multivariate analysis (P = 0.008). Recurrence was independent of presentation mode or the presence of an endophytic growth pattern (Table 1) .
Grade progression (to high-grade) was found in five patients (2.4%). This was accompanied by stage progression in three patients (1.4%). Two patients developed T2N0 disease at 8 and 12.5 years after the primary bladder tumour, respectively. One underwent radical cystectomy and one partial cystectomy. Both are alive with no evidence of recurrence at 4 and 4.1 years, respectively, after surgery. Another patient developed high-grade T1 tumour, 6.7 years after the primary bladder tumour. She was treated with BCG and had no bladder recurrence until her death from colon cancer 6 years later. All three patients had primary tumours of >1 cm. During follow-up, 23 patients died (10.9%) after a median period of 5.5 years. Death was not disease specific in any patient.
In 84 patients (40% of all patients) tumours' largest diameter was ≤1 cm. A comparison of patients with smaller tumours to patients with larger tumours is presented in Table 2 . In both uni-and multivariate analyses, patients with smaller tumours were significantly younger (64.6 vs 68.3 years, P = 0.029) and were more commonly asymptomatic at presentation (P = 0.047). The RFS rate was significantly higher in patients with smaller tumours (5-year RFS of 92% in patients with smaller tumours vs 70% in patients with larger tumours, P < 0.001).
Additionally, recurrence timing between the two groups differed ( Table 2 , and Figs 1 and 2). The median time to recurrence was 5.7 years in patients with small tumours and 2.5 years in patients with larger tumours (P = 0.003). Only 43.7% of the recurrences in patients with the smaller tumours occurred within 5 years, compared to 75.5% of the recurrences in patients with larger tumours. As can be seen in Fig. 2 , half of the recurrences in the larger-tumour group occurred within the first 4 years after the initial resection and the rest occurred in declining rate, in contrast, recurrences in the smaller-tumour group were evenly spread over 10 years. 
Discussion
In most guidelines the recommended follow-up in cases of low-risk bladder cancer includes periodic cystoscopies for 5 years [1] . Adopting the philosophy that the risk of bladder cancer recurrence never drops to zero, follow-up in our institution continues indefinitely, using annual US examination of the urinary system. This policy provided a long-term database on patients with low-risk bladder cancer.
We found a recurrence rate of 30.7% and stage progression in 1.4%. These figures match the predictions of the European Organisation for the Research and Treatment of Cancer (EORTC) risk tables (31% for recurrence and 0.8% for progression) [6] . In the three patients with stage progression, progression occurred 7.3, 8 and 12.5 years after the primary bladder tumour. These long periods suggest that these are separate carcinogenic events and not true 'progressions' of the primary tumours. All three patients with stage progression had primary tumours of >1 cm and there were no cases of disease-specific mortality.
Dividing the group of 'low-risk' patients according to tumour diameter, using a 1-cm threshold yielded two distinct subgroups (Table 2 and Fig. 1 ). Patients with smaller tumours (40% of all 'low-risk' patients) were significantly younger and had a significantly lower risk of tumour recurrence; by 1 year, only 1.1% developed recurrence, and by 5 years only 8.3%. By contrast, the 1-year recurrence rate in the subgroup with larger tumours (60% of all 'low-risk' patients) was 11% and the 5-year recurrence rate was 30% (P < 0.001). The timing of tumour recurrence of the two groups is shown in Fig. 2 . In all, 70% of recurrences in the largertumour group occurred during the first 4 years after the initial resection and the rest at a declining rate. In contrast, recurrences in the smaller-tumour group were evenly spread over a 10-year period, with more than half of the recurrences occurring beyond the recommended follow-up period of 5 years.
Taken together these data suggest that 'low-risk' bladder cancer is not a homogenous group and is composed of two distinct populations; patients with 'low-risk' tumours of ≤1 cm who are younger, are at lower risk of tumour recurrence, and their recurrences are delayed. 'Recurrence' in these patients probably represents a new event of carcinogenesis. These tumours can be termed 'very-low-risk'. Patients with low-risk tumours of >1 cm (but <3 cm) are older, have a higher risk of recurrence, and most of their recurrences occur during the first years after the initial event.
Recurrence mode here probably occurs via the classical routes of seeding and multifocality. These patients can be termed 'new-low-risk' or just 'low-risk' exactly as in prostate cancer [9] . Another possible explanation for the low frequency of recurrence of small tumours could be the different surgical technique used during their removal. Whilst small tumours are often removed en bloc, larger tumours usually require piecemeal dissection that release more potentially implantable tumour cells to the bladder lumen.
Most guidelines for follow-up after resection of a 'low risk' tumour recommend cystoscopy at 3, 12, 24, 26, 48 and 60 months after primary tumour resection [1] [2] [3] . These recommendations are based on combined analysis of 2 596 patients with Ta and T1 bladder cancer from seven randomised EORTC trials [6] . The median follow-up in these studies was 3.9 years. This is in contrast to a median followup of 10 years in the present study. Thus, most guidelines are based on short follow-up periods, which miss the late recurrences typical of 'very-low-risk' patients. A suggestion for the phenomenon of delayed recurrence typical to patients with low-grade Ta tumours can be found in the literature. Leblanc et al. [10] followed low-risk patients for a mean period of 6.3 years. They noted that 14% of the recurrences occurred at >5 years after the primary tumour. The median follow-up was not reported in that article and one may safely assume that with longer follow-up more recurrences would have been diagnosed. The data presented here suggests that the EORTC guidelines are adequate for patients with 'lowrisk' tumours of 1.1-3 cm in diameter and diagnose 75% of the recurrences.
Different follow-up is recommended by the NICE guidelines [4] , which suggest follow-up cystoscopy at 3 and 12 months after diagnosis, and then discharge to primary care. Whilst these guidelines definitely consider the low risk of tumour progression or metastases they ignore the risk of late recurrence. Assuming that no further follow-up will be conducted by the primary care physician, this policy would miss 49/65 (75%) of the recurrences in the present series, which comprises 23% of all patients with 'low-risk' bladder cancer.
So what can be offered to patients with 'very-low-risk' bladder cancer that have almost a zero risk of progression and a low risk of recurrence which is late? Transabdominal US is a non-invasive, cheap, repeatable and reproducible method, which is readily available. It requires minimal preparation and does not involve ionising radiation [11] . The sensitivity of US for bladder cancer is dependent on tumour size. US detects 82-100% of tumours >5 mm [12] [13] [14] . Its detection rate is much lower (0-57%) for smaller tumours [15] . Is it safe to miss recurrences that are <5 mm in patients with 'very-low-risk' disease? Studies in surveillance without resection of small recurrent tumours in patients with history of 'low-risk' disease showed that this policy is very safe from the oncological point of view (no progressions) and very few patients become symptomatic [16, 17] . Thus, for the patients with 'very-low-risk' disease, cystoscopy at 3 months for quality control of the first surgery and afterwards annual US evaluation for 10 years is a reasonable surveillance protocol. For patients with larger 'low-risk' tumours the current guidelines seem very appropriate.
The present study has several limitations, including the retrospective nature of data analysis and the source of data from a single institution. The strength of the study is the purity of the data, the stability of the protocol, and the long follow-up that seems necessary for evaluation of recurrence in this category of patients. Validation of the findings by other investigators is certainly necessary.
Conclusions
About 40% of the patients with low-risk bladder cancer present with tumours of <1 cm. Compared to patients with low-risk tumours between 1.1 and 3 cm in diameter, these patients are younger, have significantly lower risk of tumour recurrence, and most of their recurrences occur beyond the recommended 5-year surveillance period. Taken together, it seems that these patients can be classified separately to a 'very-low-risk' group. Follow-up in these cases can be based on prolonged US evaluations after the initial 3-month followup cystoscopic evaluation.
